BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 38643482)

  • 21. ESR1 genetic alterations and their association with clinicopathologic characteristics in advanced breast cancer: a single academic institution experience.
    Freitag CE; Mei P; Wei L; Parwani AV; Li Z
    Hum Pathol; 2021 Jan; 107():80-86. PubMed ID: 33157125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer.
    Giamas G; Filipović A; Jacob J; Messier W; Zhang H; Yang D; Zhang W; Shifa BA; Photiou A; Tralau-Stewart C; Castellano L; Green AR; Coombes RC; Ellis IO; Ali S; Lenz HJ; Stebbing J
    Nat Med; 2011 Jun; 17(6):715-9. PubMed ID: 21602804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ESR1 mutations in breast cancer.
    Dustin D; Gu G; Fuqua SAW
    Cancer; 2019 Nov; 125(21):3714-3728. PubMed ID: 31318440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer.
    Kondo N; Toyama T; Sugiura H; Fujii Y; Yamashita H
    Cancer Res; 2008 Jul; 68(13):5004-8. PubMed ID: 18593897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preexisting Somatic Mutations of Estrogen Receptor Alpha (
    Dahlgren M; George AM; Brueffer C; Gladchuk S; Chen Y; Vallon-Christersson J; Hegardt C; Häkkinen J; Rydén L; Malmberg M; Larsson C; Gruvberger-Saal SK; Ehinger A; Loman N; Borg Å; Saal LH
    JNCI Cancer Spectr; 2021 Apr; 5(2):. PubMed ID: 33937624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endocrine resistance in breast cancer--An overview and update.
    Clarke R; Tyson JJ; Dixon JM
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 3(0 3):220-34. PubMed ID: 26455641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oestrogen receptor negativity in breast cancer: a cause or consequence?
    Gajulapalli VNR; Malisetty VL; Chitta SK; Manavathi B
    Biosci Rep; 2016 Dec; 36(6):. PubMed ID: 27884978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer.
    Xia S; Lin Q
    Technol Cancer Res Treat; 2022; 21():15330338221090351. PubMed ID: 35450488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of resistance to estrogen receptor modulators in ER+/HER2- advanced breast cancer.
    Zhang J; Wang Q; Wang Q; Cao J; Sun J; Zhu Z
    Cell Mol Life Sci; 2020 Feb; 77(4):559-572. PubMed ID: 31471681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
    Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
    Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. USP35, regulated by estrogen and AKT, promotes breast tumorigenesis by stabilizing and enhancing transcriptional activity of estrogen receptor α.
    Cao J; Wu D; Wu G; Wang Y; Ren T; Wang Y; Lv Y; Sun W; Wang J; Qian C; He L; Yang K; Li H; Gu H
    Cell Death Dis; 2021 Jun; 12(6):619. PubMed ID: 34131114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MiR-301a-3p Suppresses Estrogen Signaling by Directly Inhibiting ESR1 in ERα Positive Breast Cancer.
    Lettlova S; Brynychova V; Blecha J; Vrana D; Vondrusova M; Soucek P; Truksa J
    Cell Physiol Biochem; 2018; 46(6):2601-2615. PubMed ID: 29763890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heat shock factor 1 (HSF1) cooperates with estrogen receptor α (ERα) in the regulation of estrogen action in breast cancer cells.
    Vydra N; Janus P; Kus P; Stokowy T; Mrowiec K; Toma-Jonik A; Krzywon A; Cortez AJ; Wojtas B; Gielniewski B; Jaksik R; Kimmel M; Widlak W
    Elife; 2021 Nov; 10():. PubMed ID: 34783649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ZBTB7A governs estrogen receptor alpha expression in breast cancer.
    Molloy ME; Lewinska M; Williamson AK; Nguyen TT; Kuser-Abali G; Gong L; Yan J; Little JB; Pandolfi PP; Yuan ZM
    J Mol Cell Biol; 2018 Aug; 10(4):273-284. PubMed ID: 30265334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
    Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.
    Leary AF; Drury S; Detre S; Pancholi S; Lykkesfeldt AE; Martin LA; Dowsett M; Johnston SR
    Clin Cancer Res; 2010 Mar; 16(5):1486-97. PubMed ID: 20179226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance.
    Katzenellenbogen JA; Mayne CG; Katzenellenbogen BS; Greene GL; Chandarlapaty S
    Nat Rev Cancer; 2018 Jun; 18(6):377-388. PubMed ID: 29662238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing.
    Ross DS; Zehir A; Brogi E; Konno F; Krystel-Whittemore M; Edelweiss M; Berger MF; Toy W; Chandarlapaty S; Razavi P; Baselga J; Wen HY
    Mod Pathol; 2019 Jan; 32(1):81-87. PubMed ID: 30158597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer.
    Swetzig WM; Wang J; Das GM
    Oncotarget; 2016 Mar; 7(13):16049-69. PubMed ID: 26909605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth.
    Tolhurst RS; Thomas RS; Kyle FJ; Patel H; Periyasamy M; Photiou A; Thiruchelvam PT; Lai CF; Al-Sabbagh M; Fisher RA; Barry S; Crnogorac-Jurcevic T; Martin LA; Dowsett M; Charles Coombes R; Kamalati T; Ali S; Buluwela L
    Breast Cancer Res Treat; 2011 Jul; 128(2):357-68. PubMed ID: 20730598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.